Repligen Corporation (RGEN)
SurévaluéFondamental
55
Prix
$192.23
Capitalisation boursière
$10.85B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$785M
12 derniers mois (au 30/06/2026)
Résultat net
$42M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$94M
Capitaux propres totaux
$2.11B
Passif total
$844M
Ratio de liquidité général
9.05
Couverture des intérêts
2.92
Dette/EBITDA
5.16
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$133.58
Prix actuel
$192.23
Marge de sécurité
-43.9%
Fourchette de juste valeur
$86.83 - $180.34
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
259.77
ROE
2.3%
Ratio P/B
5.14
P/FCF
96.89
Marge brute
53.5%
ROIC
1.8%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
1.8%
WACC
10.2%
ROIC − WACC
-8.4 pp
Le ROIC est inférieur au coût du capital — l'entreprise détruit de la valeur pour chaque dollar investi.
Critères d'analyse fondamentale
Réussi (17)
- EPS shows upward trend
- Price CAGR 19.60%
- Gross Margin 53.5%
- Debt/Equity ratio
- Operating Margin 8.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 15.1%
- Analyst Consensus 86% Buy
- Earnings Surprise avg 14.2%
- Earnings Quality (OCF/NI) 3.25
- Net Margin Trend 5.3% vs -2.1%
- Piotroski F-Score 7/9
Échoué (8)
- ROIC 1.8%
- P/FCF 96.89
- P/B Ratio 5.14
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 2.0%
- Share Dilution 2.5%
Indisponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Émission de nouvelles actions, diluant la participation
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Olivier Loeillot | President, CEO & Director | 55 |
| Mr. Jason K. Garland | CFO & Chief Compliance Officer | 51 |
| Mr. James R. Bylund | Chief Operating Officer | 62 |
| Mr. Anthony J. Hunt | Advisor | 61 |
| Mr. Ralf Kuriyel | Senior Vice President of Research & Development | 67 |
| Mr. Brian Douglass | Senior VP & Chief Product Officer | 50 |
| Ms. Violetta Hughes | Chief Accounting Officer | 52 |
| Ms. Heather Ems | Chief Information Officer | - |
| Mr. Jacob K. Johnson C.F.A. | Vice President of Investor Relations | - |
| Mr. George A Scott Jr., J.D., M.B.A. | Senior VP & General Counsel | - |
Risque d'audit
10
Risque du conseil
4
Risque de rémunération
5
Risque droits des actionnaires
1
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-02-26
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-07-29
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-09-15
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for RGEN, sourced from Markets Gazette.
- 2/24/2026NEUTRALRepligen (RGEN) Q4 2025 Earnings Call Transcript
Markets Gazette reports that the transcript for Repligen Corporation's (RGEN) Q4 2025 earnings call is now available. While specific details are not disclosed here, investors and analysts eagerly await an in-depth review of this document. Earnings call transcripts are crucial for understanding past financial performance, future projections, and corporate strategies. Market participants will be looking for insights into revenues, margins, product pipeline, and management's commentary regarding the life sciences sector outlook. The availability of such information is a standard event in the financial calendar, but its market impact will entirely depend on the data and statements contained within, which will guide future investment decisions.
via Markets Gazette